

1 **Evaluation of commercial anti-SARS-CoV-2 antibody assays and comparison of**
2 **standardized titers in vaccinated healthcare workers.**

3

4 Kahina Saker¹, Vanessa Escuret^{1,4}, Virginie Pitiot², Amélie Massardier-Pilonchéry², Stéphane
5 Paul³, Bouchra Mokdad¹, Carole Langlois-Jacques⁵, Muriel Rabilloud⁵, David Goncalves⁶,
6 Nicole Fabien⁶, Nicolas Guibert², Jean-Baptiste Fassier², Antonin Bal¹, Sophie Trouillet-
7 Assant^{1,4}, Mary-Anne Trabaud¹.

8

9 ¹Laboratoire de Virologie, Institut des Agents Infectieux, Laboratoire associé au Centre
10 National de Référence des virus des infections respiratoires, Hospices Civils de Lyon, IAI,
11 Centre de Biologie Nord, Groupement Hospitalier Nord, F-69317, Lyon Cedex 04, France

12 ²Occupational Health and Medicine Department, Hospices Civils de Lyon, Lyon, France

13 ³Laboratory of Immunology and Immunomonitoring, CIC 1408 INSERM, GIMAP EA3064,
14 University Hospital of Saint-Etienne, F-42055, Saint-Etienne cedex 2, France

15 ⁴CIRI- International Center of Research in Infectiology, INSERM U1111, CNRS UMR5308,
16 ENS Lyon, Claude Bernard Lyon 1 University, F-69008, Lyon, France.

17 ⁵CNRS, UMR 5558, University of Lyon, Laboratoire de Biométrie et Biologie Evolutive,
18 Equipe Biostatistique-Santé, F-69100, Villeurbanne, France

19 ⁶Immunology Department, Lyon Sud Hospital, Hospices Civils de Lyon, F-69495, Pierre-
20 Bénite cedex, France

21 **Corresponding author**

22 Mary-Anne Trabaud, mary-anne.trabaud01@chu-lyon.fr

23 **Running title:** Comparison of SARS-CoV-2 antibody titers after vaccination

24 **Keywords:** SARS-CoV-2 antibodies; quantification; commercial assays; standardized titers;
25 vaccination; health care workers

26 **Abstract**

27 With the availability of vaccines, commercial assays detecting anti-SARS-CoV-2 antibodies
28 (Ab) evolved towards quantitative assays directed to the spike glycoprotein or its receptor
29 binding domain (RBD). The main objective of the present study was to compare the Ab titers
30 obtained with quantitative commercial binding Ab assays, after 1 dose (convalescent
31 individuals) or 2 doses (naïve individuals) of vaccine, in healthcare workers (HCW).

32 Antibody titers were measured in 255 sera (from 150 HCW) with 5 quantitative
33 immunoassays (Abbott RBD IgG II quant, bioMérieux RBD IgG, DiaSorin Trimeric spike
34 IgG, Siemens Healthineers RBD IgG, Wantai RBD IgG). One qualitative total antibody anti
35 RBD detection assay (Wantai) was used to detect previous infection before vaccination. The
36 results are presented in binding Ab units (BAU)/mL after application, when possible, of a
37 conversion factor provided by the manufacturers and established from a World Health
38 Organization (WHO) internal standard.

39 There was a 100% seroconversion with all assays evaluated after two doses of vaccine. With
40 assays allowing BAU/ml correction, Ab titers were correlated (Pearson correlation
41 coefficient, ρ , range: 0.85-0.94). The titer differences varied by a mean of 10.6% between
42 Siemens and bioMérieux assays to 60.9% between Abbott and DiaSorin assays. These results
43 underline the importance of BAU conversion for the comparison of Ab titer obtained with the
44 different quantitative assays. However, significant differences persist, notably, between kits
45 detecting Ab against the different antigens.

46 A true standardization of the assays would be to include the International Standard in the
47 calibration of each assays to express the results in IU/mL.

48

49 **Introduction**

50 Since the end of 2020, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
51 vaccines have become available worldwide with the aim of achieving herd immunity to
52 control the pandemic. Vaccine immunity involves both cellular and humoral pathways.
53 Cellular immunity is not easy to assess on a large scale, as is the neutralizing humoral
54 response owing to requirement for a biosafety level 3 (BSL3) containment laboratory. The
55 evaluation of vaccine effectiveness therefore mainly relies on high throughput serological
56 tests to assess individual humoral immunity as well as monitoring SARS-CoV-2
57 seroprevalence (1).

58 To effectively utilize measurements of binding antibodies (Ab) as indicators of vaccine
59 effectiveness, several conditions must be met. First, binding Ab assays should be quantitative;
60 second, titers should be consistent between different assays; third, binding Ab titers should
61 correlate with neutralizing Ab titers; fourth, the minimum binding Ab titer associated with
62 virus neutralization must be found; and fifth, the association between neutralizing Ab and
63 vaccine protection must be demonstrated. It can be considered that the first and fifth
64 conditions have been met given that commercial tests for the quantitative detection of binding
65 Ab have been developed (2–8), and that the role of neutralizing Ab in the infection protection
66 have been demonstrated in animals and humans (9-12). This is not the case for the other
67 conditions; in particular, the second point is of importance for widespread evaluation of
68 vaccines, but until now, Ab titers were often expressed as an index or unit with regard to an
69 internal standard that differs between manufacturers. Recently, the World Health
70 Organization (WHO) has developed an international standard (13) against which each
71 supplier can standardize their assay, allowing comparability of titers between kits. The present
72 study was conducted to evaluate the performance of commercial antibody assays in detecting
73 vaccination-associated anti-SARS-CoV-2 Ab seroconversion; the main objective was to

74 compare Ab titers from quantitative assays after conversion of titers with the conversion
75 factor obtained using the WHO standard and provided by each manufacturer.

76

77 **Materials and Methods**

78 **Antibody binding assays**

79 Six CE-marked Ab binding assays, validated by each manufacturer, were investigated
80 according to the protocol recommended by each manufacturer (the characteristics of the
81 assays are summarized in Table 1). Five were quantitative: Siemens Healthineers (Erlangen,
82 Germany) Atellica® IM SARS-CoV-2 IgG (sCOVG; used in routine in our laboratory),
83 DiaSorin (Saluggia, Italy) Liaison® SARS-CoV-2 TrimericS IgG, bioMérieux (Marcy
84 l'Etoile, France) Vidas® SARS-CoV-2 IgG (clinically used for confirmation if necessary),
85 Abbott (Abbott park, IL, USA) Architect SARS-CoV2 IgG II Quant, and Wantai (Beijing,
86 China) SARS-CoV-2 IgG assays. The Wantai SARS-CoV-2 total antibody assay is qualitative
87 and was selected to detect a previous infection before vaccination based on its better
88 sensitivity in infected individuals compared to other commercial qualitative assays we have
89 evaluated in a previous study (14). The First International Standard developed by the WHO
90 (National Institute for Biological Standards and Control code: 20/136) corresponds to
91 lyophilized pooled plasma from patients who had been infected with SARS-CoV-2; after
92 reconstitution, the solution contains 1000 binding antibody units (BAU) per mL (13).

93 For conversion of titers obtained using the quantitative assays, the concentrations expressed in
94 arbitrary units per mL, or index according to the assay (Table 1), were converted to BAU/mL
95 using the conversion factors provided a posteriori (not included in the main procedure but as a
96 separate document – either by electronic or postal mail) by the manufacturer (with the
97 exception of the Wantai SARS-CoV-2 IgG assay for which the conversion factor was not
98 available and presented here only to compare the positivity rate between assays); these were

99 21.8 for the Siemens assay, 2.6 for the DiaSorin assay, 20.33 for the bioMérieux assay, and
100 0.142 for the Abbott assay (considering that 1 BAU/mL = conversion factor x AU/mL or
101 index). Samples with results above the upper limit of quantification were tested again after
102 dilution (1/5 when above 3270 BAU/mL for the Siemens assay, 1/20 when above 2080
103 BAU/mL for the DiaSorin assay, 1/20 when above 18 index for the bioMérieux assay, and 1/2
104 when above 5680 BAU/mL for the Abbott assay).

105 **Samples from the study population**

106 A prospective longitudinal cohort study was conducted at the laboratory associated with the
107 national reference center for respiratory viruses (University Hospital of Lyon, France).
108 Healthcare workers, excluding pregnant women (HCW; n=150) who were scheduled to
109 receive 2 doses of Pfizer BioNtech vaccine (n=94; BNT162b2/BNT162b2; 78% female;
110 median age 48.5 [range: 21-76] years) or 1 dose of AstraZeneca vaccine followed by 1 dose
111 of Pfizer BioNtech vaccine (n=56; ChAdOx1/BNT162b2; 70% female; median age 33.5
112 [range: 21-55] years) were included. Blood samples were collected i) before the first dose of
113 vaccine, ii) before the second injection of vaccine corresponding to 4 weeks after the first
114 dose for participants vaccinated with 2 doses of Pfizer BioNtech vaccine (median delay of 28
115 [range: 21-37] days) or 12 weeks for those vaccinated with the AstraZeneca vaccine (median
116 delay of 85 [range: 84-97] days), and iii) 4 weeks after the full vaccination. The pre-
117 vaccination blood sample was used to document a previous SARS-CoV-2 infection. Among
118 the participants, 26 who were previously infected with SARS-CoV-2 (convalescent group;
119 17.4%) had only one vaccine injection (Pfizer BioNtech, n=15 or Astra Zeneca, n=11); for
120 these the second sample was omitted. Three participants were infected with SARS-CoV-2
121 between the 2 doses. Serum samples were prepared from 5 mL of whole blood collected in
122 BD Vacutainer[®] Serum Separator Tubes II Advance (Beckon Dickinson Diagnostics). After
123 collection, tubes were shaken gently and serum allowed to clot for a minimum 30 min at room

124 temperature to obtain total coagulation, followed by centrifugation at 2,000 g for 10 min.
125 Serum removed from gel was stored at -80°C until serological assays were performed.
126 Written informed consent was obtained from all participants; ethics approval was obtained
127 from the regional review board for biomedical research in April 2020 (*Comité de Protection*
128 *des Personnes Sud Méditerranée I*, Marseille, France; ID RCB 2020-A00932-37), and the
129 study was registered on ClinicalTrials.gov (NCT04341142).

130 **Statistical analyses**

131 Results were expressed by the median and interquartile range [IQR]. Paired comparison
132 between assays was performed using the Wilcoxon test. The correlation between
133 concentrations obtained by each assay was investigated using Pearson correlation coefficients
134 and 95% confidence interval (CI). To estimate proportional bias between two methods,
135 Passing and Bablok regression was used and the regression line equation was calculated from
136 the two data sets. The Bland-Altman method was used to measure the mean difference and
137 95% limit of agreement between log-transformed concentrations obtained with each assay.
138 Statistical analyses were conducted using GraphPad Prism® software (version 8; GraphPad
139 software, La Jolla, CA, USA). A p-value <0.05 was considered statistically significant.

140

141 **Results**

142 In the first part of the study, the performances of the six assays were compared to verify
143 whether the ability to detect anti-SARS-CoV-2 antibodies of the Wantai total Ab assay,
144 previously found as the most sensitive post-infection compared to other commercial
145 qualitative assays (14), was similar after vaccination, and whether the sensitivity of qualitative
146 and quantitative assays were also similar. The sera collected from patients scheduled to
147 receive only Pfizer BioNtech vaccine (two doses 3 to 4 weeks apart, n=79) were used for this

148 evaluation. Four weeks after the first injection, the proportion of positive samples was over
149 90% for all assays except the Wantai assay detecting total antibodies (86.1%). Only one
150 sample was negative with all assays. Six samples were negative with only one assay (5 with
151 the Wantai total Ig assay, 1 with the Wantai IgG assay). Four samples were negative with 3 to
152 5 assays. In all of these cases the signals from positive assays were low. Four weeks after the
153 second injection anti SARS CoV-2 antibodies were detected for all participants with all the
154 assays (Table 1).

155 The second part of this study was to compare Ab titers after BAU/mL conversion; for this,
156 only the assays adapted or developed for the quantification of Ab were tested. The Siemens,
157 DiaSorin, bioMérieux and Abbott assays were compared using sera samples collected before
158 the second injection of vaccine and those collected after full vaccination, and for which assays
159 gave a positive quantitative result (255 samples). The median [IQR] values obtained were
160 744.9 [108.1; 2482] BAU/mL for the Siemens, 1240 [262.6; 3370] BAU/mL for the DiaSorin,
161 951.4 [142.5; 2314] BAU/mL for the bioMérieux, and 768.9 [100.8; 1916] BAU/mL for the
162 Abbott assays; there was a significant difference in median titers between DiaSorin and
163 Siemens ($p < 0.0001$), between DiaSorin and bioMérieux ($p < 0.0001$), as well as between
164 Abbott and each assay ($p < 0.0001$). The difference in median titers between Siemens and
165 bioMérieux assays was not significant (Figure 1). There was a strong correlation between
166 assays (Table 2).

167 The slopes of the Passing and Bablock regression curves were calculated by pairwise
168 comparison of each assay. The deviation from the perfect correlation was significantly greater
169 between DiaSorin and each of the other assays than between each of these other assays. In
170 most cases, there was a proportional difference between assays (Figure 2). In particular,
171 DiaSorin assay values reached higher levels than the other methods; 11 samples had a value

172 above 10,000 BAU/ml while only three reached this threshold with the Siemens assay and
173 none with the BioMérieux and Abbott assays.

174 According to the Bland-Altman method there was a mean [95%CI] difference in titers
175 expressed as BAU concentrations of 50.9% [46.4%; 55.3%] between the Siemens and
176 DiaSorin assays, 40.4% [35.5%; 45.3%] between bioMérieux and DiaSorin assays, 60.9%
177 [55.9%; 66%] between Abbott and DiaSorin assays, 10.6% [5.8%; 15.4%] between Siemens
178 and bioMérieux assays, 12.1% [16.2%; 8%] between Siemens and Abbott assays, and 22.3%
179 [17.5%; 27.1%] between Abbott and bioMérieux assays (Figure 3).

180

181 **Discussion**

182 In the present cohort of vaccinated HCW, the performance of qualitative serological assays,
183 developed for diagnostic purposes at the beginning of the pandemic, as well as those adapted
184 or developed when the vaccine became available, were similar. However, assays developed
185 for detecting a past infection are not useful to monitor vaccination effectiveness since they are
186 not quantitative or could not be compared to others. The more important finding of the
187 present study was that the quantitative assays, whose results could be standardized to
188 BAU/ml, produce results that are correlated to each other. The Ab titers obtained with the
189 DiaSorin assay, although correlated with those of the other assays, remained higher after
190 conversion using the WHO standard. This may be related to difference in the antigens
191 targeted, as the DiaSorin assay is the only one evaluated in this study, to use the trimeric spike
192 protein (2). The WHO standard was obtained from the plasma of convalescent patients (13)
193 and must therefore contain antibodies against numerous epitopes, thus the DiaSorin assay is
194 probably capable of reacting with more antibodies than assays detecting only antibodies
195 specific for RBD.

196 There are currently very few reports that have examined Ab binding assays with the use of the
197 WHO standard (3, 7). Perkman et al. (7) compared four assays detecting binding Ab,
198 including the Liaison anti SARS-CoV-2 trimeric S IgG from DiaSorin and the Architect anti
199 SARS-CoV-2 RBD IgG from Abbott, used in the present study. In vaccinated individuals,
200 after the first dose of vaccine, titers varied significantly between the assays, but they indicated
201 that the recalculation in BAU/ml with the conversion factor given by the manufacturer did not
202 solve error problems between tests. However, the assays compared were more different in
203 their format than those investigated herein: total anti-RBD Ig versus anti-RBD IgG, anti-
204 monomeric spike IgG or anti-trimeric spike IgG. Interestingly, comparison of Abbott and
205 DiaSorin assays found, as was the case herein, higher titers for the DiaSorin assay. Later,
206 Bradley et al. (3) performed linear regressions from sample dilutions of the WHO standard to
207 determine a detection limit in international units (IU) per ml for each test; the authors
208 confirmed the linearity of the Abbott anti-SARS-CoV-2 IgG II Quant assay over the
209 analytical measurement interval but the conversion factor found seemed to be higher than
210 indicated by the manufacturer (1 IU/ml gave 6,1 arbitrary units/ml while Abbott indicated that
211 1 IU correspond to 7.1 arbitrary units). Taken together, these data suggest that there are
212 remaining differences between assays after conversion in BAU/ml and that this could be due
213 to the incorrect adjustment of the correction factor by the manufacturers. The next step for a
214 true harmonization would therefore be to use the international standard to calibrate each assay
215 instead of applying a conversion factor to a result obtained with an assay previously calibrated
216 with an internal standard (15).

217 A limitation of this study is the absence of specificity analysis. However, assay specificity
218 analyses have been performed by manufacturers and independent groups (2, 4–6) showing
219 specificity $\geq 99\%$ for all the quantitative assays. A point that may be also considered as a
220 limitation is the choice to use the conversion factors obtained by the manufacturers without

221 testing the WHO standard ourselves; but the aim of the present study was to evaluate these
222 assays under the conditions offered by the manufacturers to all their customers. In addition,
223 not all commercial quantitative anti-SARS-CoV-2 Ab assays were evaluated, limiting the
224 scope of the conclusions. Furthermore, neutralizing Ab were not investigated that could have
225 helped determine whether anti-RBD or anti-spike assays are the most correlated with virus
226 neutralization. However, before investigating this, harmonization of neutralizing Ab titers is
227 also necessary to determine a common threshold from which vaccine protection could be
228 predicted, allowing then to find the corresponding threshold with high throughput binding Ab
229 assays. A study comparing different cell-based assays (with either live or pseudotyped
230 viruses) to measure neutralization in vitro is rather reassuring, although differences were
231 found according to the viruses used for pseudotyping (16). However, comparison of cell-
232 based assays with surrogate virus neutralization tests (sVNT) that are based on ELISA, and
233 measuring the competition of Ab and RBD for the binding to ACE, the cellular entry receptor
234 of the virus, did not find good agreement; this is inconvenient, as these assays could be
235 promising given that they have potential for large-scale.

236 In conclusion, the evaluated assays correlated well with each other but a difference in titers
237 remained after adjustment to the same International Standard. Thus, the titer harmonization is
238 not yet completely achieved, but it is better between assays detecting the same Ab against the
239 same antigen than between assays with different targets.

240

241 **Acknowledgements**

242 This study was supported by Hospices Civils de Lyon and Fondation des Hospices Civils de
243 Lyon. The respective suppliers kindly provided all the serological kits used in this study.

244 We thank all the staff members of the occupational health and medicine department of the
245 Hospices Civils de Lyon who contributed to the sample collection. We thank all Clinical

246 Research Associates, for their excellent work. We thank Karima Brahima and all the members
247 of the clinical research and innovation department for their reactivity (DRCI, Hospices Civils
248 de Lyon). Human biological samples and associated data were obtained from NeuroBioTec
249 (CRB HCL, Lyon France, Biobank BB-0033-00046). We thank all the technicians from the
250 virology laboratory of the Hospices Civils de Lyon who performed the assays on the
251 automated platforms. Lastly, we thank all the healthcare workers for their participation in this
252 clinical study, and Philip Robinson for critical reading of the manuscript and language
253 revision.

254

255 **References**

- 256 1. Shi A. C., Ren P. SARS-CoV-2 Serology Testing: Progress and Challenges. 2021. J
257 Immunol Methods 494 113060. <https://doi.org/10.1016/j.jim.2021.113060>
- 258 2. Bonelli F., Blocki F. A., Bunnell T., Chu E., De La O A., Grenache D. G., Marzucchi
259 G., Montomoli E., Okoye L., Pallavicini L., Strega V. A., Torelli A., Wagner A., Zanin
260 D., Zierold C., Wassenberg J. J. Evaluation of the Automated LIAISON® SARS-CoV-
261 2 TrimericS IgG Assay for the Detection of Circulating Antibodies. 2021. Clin Chem
262 Lab Med 59 (8) 1463–1467. <https://doi.org/10.1515/cclm-2021-0023>.
- 263 3. Bradley B. T., Bryan A., Fink S. L., Goecker E. A., Roychoudhury P., Huang M.-L.,
264 Zhu H., Chaudhary A., Madarampalli B., Lu J. Y. C., Strand K., Whimbey E., Bryson-
265 Cahn C., Schippers A., Mani N. S., Pepper G., Jerome K. R., Morishima C., Coombs R.
266 W., Wener M., Cohen S., Greninger A. L. Anti-SARS-CoV-2 Antibody Levels
267 Measured by the Advise Dx SARS-CoV-2 Assay Are Concordant with Previously
268 Available Serologic Assays but Are Not Fully Predictive of Sterilizing Immunity.
269 2021. J Clin Microbiol JCM0098921. <https://doi.org/10.1128/JCM.00989-21>.

- 270 4. English E., Cook L. E., Piec I., Dervisevic S., Fraser W. D., John W. G. Performance of
271 the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New
272 Variants of Concern (VOC 202012/V1 (UK) and VOC 202012/V2 (South Africa)):
273 And First Steps towards Global Harmonization of COVID-19 Antibody Methods.
274 2021. J Clin Microbiol JCM0028821 <https://doi.org/10.1128/JCM.00288-21>.
- 275 5. Irsara C., Egger A. E., Prokop W., Nairz M., Loacker L., Sahanic S., Pizzini A.,
276 Sonnweber T., Holzer B., Mayer W., Schennach H., Loeffler-Ragg J., Bellmann-Weiler
277 R., Hartmann B., Tancevski I., Weiss G., Binder C. J., Anliker M., Griesmacher A.,
278 Hoermann G. Clinical Validation of the Siemens Quantitative SARS-CoV-2 Spike IgG
279 Assay (SCOVG) Reveals Improved Sensitivity and a Good Correlation with Virus
280 Neutralization Titers. 2021. Clin Chem Lab Med 59 (8) 1453–1462.
281 <https://doi.org/10.1515/cclm-2021-0214>.
- 282 6. Narasimhan M., Mahimainathan L., Araj E., Clark A. E., Markantonis J., Green A., Xu
283 J., SoRelle J. A., Alexis C., Fankhauser K., Parikh H., Wilkinson K., Reczek A.,
284 Kopplin N., Yekkaluri S., Balani J., Thomas A., Singal A. G., Sarode R., Muthukumar
285 A. Clinical Evaluation of the Abbott Alinity SARS-CoV-2 Spike-Specific Quantitative
286 IgG and IgM Assays among Infected Recovered and Vaccinated Groups. 2021. J Clin
287 Microbiol 59 (7) e0038821. <https://doi.org/10.1128/JCM.00388-21>.
- 288 7. Perkmann T., Perkmann-Nagele N., Koller T., Mucher P., Radakovics A., Marculescu
289 R., Wolzt M., Wagner O. F., Binder C. J., Haslacher H. Anti-Spike Protein Assays to
290 Determine SARS-CoV-2 Antibody Levels: A Head-to-Head Comparison of Five
291 Quantitative Assays. 2021. Microbiol Spectr 9 (1) e0024721.
292 <https://doi.org/10.1128/Spectrum.00247-21>.
- 293 8. Di Meo A, Miller JJ, Fabros A, Brinc D, Hall V, Pinzon N, Ierullo M, Ku T, Ferreira
294 VH, Kumar D, Pasic MD, Kulasingam V. 2021. Evaluation of Three anti-SARS-CoV-2

- 295 Serologic Immunoassays for Post-Vaccine Response. *J Appl Lab Med*.
- 296 <https://doi.org/10.1093/jalm/jfab087>.
- 297 9. Addetia A., Crawford K. H. D., Dingens A., Zhu H., Roychoudhury P., Huang M.-L.,
298 Jerome K. R., Bloom J. D., Greninger A. L. Neutralizing Antibodies Correlate with
299 Protection from SARS-CoV-2 in Humans during a Fishery Vessel Outbreak with a
300 High Attack Rate. 2020. *J Clin Microbiol* 58 (11) e02107-20.
301 <https://doi.org/10.1128/JCM.02107-20>.
- 302 10. Letizia A. G., Ge Y., Vangeti S., Goforth C., Weir D. L., Kuzmina N. A., Balinsky C.
303 A., Chen H. W., Ewing D., Soares-Schanoski A., George M.-C., Graham W. D., Jones
304 F., Bharaj P., Lizewski R. A., Lizewski S. E., Marayag J., Marjanovic N., Miller C. M.,
305 Mofsowitz S., Nair V. D., Nunez E., Parent D. M., Porter C. K., Santa Ana E.,
306 Schilling M., Stadlbauer D., Sugiharto V. A., Termini M., Sun P., Tracy R. P.,
307 Krammer F., Bukreyev A., Ramos I., Sealfon S. C. SARS-CoV-2 Seropositivity and
308 Subsequent Infection Risk in Healthy Young Adults: A Prospective Cohort Study.
309 2021. *Lancet Respir Med* 9 (7) 712–720.
310 [https://doi.org/10.1016/S2213-2600\(21\)00158-2](https://doi.org/10.1016/S2213-2600(21)00158-2)
- 311 11. McMahan K., Yu J., Mercado N. B., Loos C., Tostanoski L. H., Chandrashekar A., Liu
312 J., Peter L., Atyeo C., Zhu A., Bondzie E. A., Dagotto G., Gebre M. S., Jacob-Dolan
313 C., Li Z., Nampanya F., Patel S., Pessaint L., Van Ry A., Blade K., Yalley-Ogunro J.,
314 Cabus M., Brown R., Cook A., Teow E., Andersen H., Lewis M. G., Lauffenburger D.
315 A., Alter G., Barouch D. H. Correlates of Protection against SARS-CoV-2 in Rhesus
316 Macaques. 2021. *Nature* 590 (7847) 630–634.
317 <https://doi.org/10.1038/s41586-020-03041-6>
- 318 12. Rogers T. F., Zhao F., Huang D., Beutler N., Burns A., He W., Limbo O., Smith C.,
319 Song G., Woehl J., Yang L., Abbott R. K., Callaghan S., Garcia E., Hurtado J., Parren

- 320 M., Peng L., Ramirez S., Ricketts J., Ricciardi M. J., Rawlings S. A., Wu N. C., Yuan
321 M., Smith D. M., Nemazee D., Teijaro J. R., Voss J. E., Wilson I. A., Andrabi R.,
322 Briney B., Landais E., Sok D., Jardine J. G., Burton D. R. Isolation of Potent SARS-
323 CoV-2 Neutralizing Antibodies and Protection from Disease in a Small Animal Model.
324 2020. *Science* 369 (6506) 956–963. <https://doi.org/10.1126/science.abc7520>.
- 325 13. Mattiuzzo G., Bentley E. M., Hassall M., Routley S., Bernasconi V., Kristiansen P.,
326 Harvala H., Roberts D., Semple G., Turtle L. C., Openshaw P. J., Baillie K.,
327 Investigators C., Nissen-Meyer L. S. H., Brants A. B., Atkinson E., Rigsby P., Padley
328 D., Almond N., Rose N. J., Page M. 2020. Establishment of the WHO International
329 Standard and Reference Panel for Anti-SARS-CoV-2 Antibody. WHO/BS/2020.2403.
330 <https://www.who.int/publications/m/item/WHO-BS-2020.2403>
- 331 14. Bal A., Pozzetto B., Trabaud M.-A., Escuret V., Rabilloud M., Langlois-Jacques C.,
332 Paul A., Guibert N., D'Aubarède-Frieh C., Massardier-Pilonchery A., Fabien N.,
333 Goncalves D., Boibieux A., Morfin-Sherpa F., Pitiot V., Gueyffier F., Lina B., Fassier
334 J.-B., Trouillet-Assant S., COVID SER Study Group. Evaluation of High-Throughput
335 SARS-CoV-2 Serological Assays in a Longitudinal Cohort of Patients with Mild
336 COVID-19: Clinical Sensitivity Specificity and Association with Virus Neutralization
337 Test. 2021. *Clin Chem* 67 (5) 742–752. <https://doi.org/10.1093/clinchem/hvaa336>.
- 338 15. Kristiansen P. A., Page M., Bernasconi V., Mattiuzzo G., Dull P., Makar K., Plotkin S.,
339 Knezevic I. WHO International Standard for Anti-SARS-CoV-2 Immunoglobulin.
340 2021. *The Lancet* 397 (10282) 1347–1348. [https://doi.org/10.1016/S0140-](https://doi.org/10.1016/S0140-6736(21)00527-4)
341 [6736\(21\)00527-4](https://doi.org/10.1016/S0140-6736(21)00527-4).
- 342 16. Sholukh A. M., Fiore-Gartland A., Ford E. S., Miner M. D., Hou Y. J., Tse L. V.,
343 Kaiser H., Zhu H., Lu J., Madarampalli B., Park A., Lempp F. A., St. Germain R.,
344 Bossard E. L., Kee J. J., Diem K., Stuart A. B., Rupert P. B., Brock C., Buerger M.,

345 Doll M. K., Randhawa A. K., Stamatatos L., Strong R. K., McLaughlin C., Huang M.-
346 L., Jerome K. R., Baric R. S., Montefiori D., Corey L. Evaluation of Cell-Based and
347 Surrogate SARS-CoV-2 Neutralization Assays. 2021. J Clin Microbiol. JCM0052721.
348 <https://doi.org/10.1128/JCM.00527-21>.
349
350

351 **TABLE 1:** Performance of six commercial anti SARS-CoV-2 antibody assays.

352

| Manufacturer | Wantai | Wantai | Siemens Healthineers | DiaSorin | bioMérieux | Abbott |
|--|---------------|---------------|---------------------------------|-------------------|-------------------|------------------|
| platform | | | Atellica® IM | Liaison® | Vidas® | Architect |
| SARS-CoV-2 Detected Ab | Total Ab | IgG | IgG | IgG | IgG | IgG |
| Assay type | ELISA | ELISA | CLIA | CLIA | ELFA | CMIA |
| Antigen | RBD | RBD | RBD | Trimeric Spike | RBD | RBD |
| Positive threshold | Index = 1 | U/mL = 0 | U/mL = 1 | AU/mL = 13 | Index = 1 | AU/mL = 50 |
| Conversion factor (WHO standard) | N/A | N/A | 21.8 | 2.6 | 20.33 | 0.142 |
| Positive threshold (BAU/mL) | N/A | N/A | 21.8 | 33.8 | 20.33 | 7.1 |
| Sensitivity (%) | 94.5 | N/A | 96.41 | 99 | 96.6 | 100 |
| Specificity (%) | 100 | N/A | 99.90 | 100 | 99.9 | 99.9 |
| Positive samples, n (%) | | | | | | |
| 4 weeks after first injection (n=79) | 68 (86.1%) | 77 (97.5%) | 74 (93.6%) | 76 (96.1%) | 75 (94.9%) | 79 (100%) |

4 weeks after
full
vaccination 94 (100%) 94 (100%) 94 (100%) 94 (100%) 94 (100%) 92/92 *
(n=94) (100%)

353

354

355

356 Positivity was established according to manufacturers' instructions. Sensitivity and specificity

357 data were those described in the instruction for utilization sheet from each manufacturer.

358 Abbreviations: Ab: antibodies, Ig: immunoglobulin, ELISA: enzyme-linked immunosorbent

359 assay, CMIA: chemiluminescence microparticle immunoassay CLIA: chemiluminescence

360 immunoassay, ELFA: enzyme-linked fluorescent assay, N: number of samples, RBD:

361 Receptor Binding Domain, CI: confidence interval.

362 * 2 samples did not remain in sufficient quantity to perform the Abbott assay

363

364 **TABLE 2:** Pearson correlation coefficient (ρ [IQR]) between each assay.

| ASSAY | Abbott | bioMérieux | DiaSorin |
|------------|-------------------|-------------------|-------------------|
| Siemens | 0.91 [0.89; 0.93] | 0.85 [0.81; 0.88] | 0.94 [0.92; 0.95] |
| DiaSorin | 0.90 [0.87; 0.92] | 0.86 [0.82; 0.89] | |
| bioMérieux | 0.90 [0.87; 0.92] | | |

365 **FIG 1:** Comparison of anti SARS-CoV-2 antibodies concentration (BAU/mL) between all
366 assays in sera collected from vaccinated subjects. The statistical difference was evaluated by
367 Wilcoxon's test. Comparison of median titers between Siemens, DiaSorin, bioMérieux, and
368 Abbott assays. BAU/mL: Binding Antibodies Unit/mL. **** $p < 0.0001$. Data from patients
369 scheduled to be vaccinated with 2 doses of Pfizer BioNtech vaccine (black) or with 1 dose of
370 AstraZeneca vaccine followed by 1 dose of Pfizer BioNtech (blue) are presented.

371

372 **FIG 2:** Passing and Bablok regression analyses using the Siemens, DiaSorin, bioMérieux, and
373 Abbott assays. A, The Siemens assay compared to the DiaSorin assay. B, bioMérieux
374 compared to DiaSorin. C, Abbott compared to DiaSorin. D, Siemens compared to
375 bioMérieux. E, Siemens compared to Abbott. F, Abbott compared to bioMérieux.

376

377 **FIG 3:** Bland-Altman plots comparing agreement between concentrations determined using
378 the Siemens, DiaSorin, bioMérieux, and Abbott assays. A, The Siemens assay compared to
379 the DiaSorin assay. B, bioMérieux compared to DiaSorin. C, Abbott compared to DiaSorin.
380 D, Siemens compared to bioMérieux. E, Siemens compared to Abbott. F, Abbott compared to
381 bioMérieux. The solid blue line represents the bias between assays, the dashed blue lines
382 represent 95%CI.

383

384





